Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2015-03-24 Proxy Solicitation & In…
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2015-03-24 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes the launch of a pharmaceutical product (Relvar Ellipta) in Italy, including regulatory approval and product details. There is no financial data, earnings information, or detailed report content. The document is short (3095 characters) and serves as an announcement of a corporate event rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2015-03-20 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text references an event on March 19, 2015, specifically a press release about the outcome of an FDA advisory committee meeting related to a supplemental New Drug Application. The document includes a press release as an exhibit and is signed by the CEO. The length is 2865 characters, which is relatively short and primarily serves as an announcement of an event and a press release attachment. There are no financial statements or detailed financial data included. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-03-19 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to disclose material events. The content describes the FDA posting briefing information related to an advisory committee meeting about a drug application. It explicitly states that the information is being furnished pursuant to Item 7.01 (Regulation FD Disclosure) and is not considered "filed" for purposes of Section 18 of the Exchange Act. The document is short (4274 characters) and primarily serves as a disclosure of information availability rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed report data. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-03-17 English
Major Shareholding Notification 2015
Major Shareholding Notification
2015-03-04 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-03-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.